Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs

Japanese Journal of Clinical Oncology

Volumn 36, Issue 5, 2006, Pages 269-273

  Niho, Seiji ^a   Goto, Koichi ^a   Yoh, Kiyotaka ^a   Kim, Young Hak ^a   Ohmatsu, Hironobu ^a   Kubota, Kaoru ^a   Saijo, Nagahiro ^a   Nishiwaki, Yutaka ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Chemotherapy; CT; Interstitial lung disease; Interstitial shadow; Lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IRINOTECAN; NAVELBINE; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; INTERSTITIAL LUNG DISEASE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICAL RECORD REVIEW; MEDICAL RESEARCH; MULTIVARIATE ANALYSIS; PATIENT PARTICIPATION; PATIENT SELECTION; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RADIOGRAPHY, THORACIC; TOMOGRAPHY, X-RAY COMPUTED; X-RAY FILM;

EID: 33745714756     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyl021     Document Type: Article

References (8)

1. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-9.
2. Kris MG, Natale RB, Herbst RS, Lynch TJ, Jr., Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003;290:2149-58.
3. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003;21:2237-46.
4. Seto T, Yamamoto N. Interstitial lung disease induced by gefitinib in patients with advanced non-small cell lung cancer: Results of a West Japan Thoracic Oncology Group (WJTOG) epidemiological survey. J Clin Oncol 2004;22:632s.
5. Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer 2004;91(Suppl 2):S18-23.
6. Niho S, Kubota K, Goto K, Yoh K, Ohmatsu H, Kakinuma R, et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 2006;24:64-9.
7. Takeda K, Negoro S, Tamura T, Nishiwaki Y, Kudoh S, Fukuda H, et al. Docetaxel versus docetaxel plus gemcitabine for second-line treatment of non-small cell lung cancer: Results of a JCOG randomized trial (JCOG0104). J Clin Oncol 2004;22:625s.
8. Kunitoh H, Watanabe K, Onoshi T, Furuse K, Niitani H, Taguchi T. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: A Japanese cooperative study. J Clin Oncol 1996;14:1649-55.